Sitagliptin and metformin (DrugBank: Metformin, Sitagliptin)
21 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 0 |
6 | パーキンソン病 | 1 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 0 |
60 | 再生不良性貧血 | 0 |
67 | 多発性嚢胞腎 | 0 |
75 | クッシング病 | 0 |
77 | 下垂体性成長ホルモン分泌亢進症 | 0 |
81 | 先天性副腎皮質酵素欠損症 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
113 | 筋ジストロフィー | 0 |
127 | 前頭側頭葉変性症 | 0 |
158 | 結節性硬化症 | 0 |
206 | 脆弱X症候群 | 0 |
225 | 先天性腎性尿崩症 | 0 |
233 | ウォルフラム症候群 | 1 |
265 | 脂肪萎縮症 | 0 |
285 | ファンコニ貧血 | 0 |
299 | 嚢胞性線維症 | 0 |
301 | 黄斑ジストロフィー | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000029465 | 2020-04-06 | 2020-02-02 | Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes | Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes | Type 2 Diabetes | Sitagliptin group:Sitagliptin 100mg/d for 52 weeks;metformin group:metformin 1000-1500mg/d for 52 weeks; | Peking Union Medical College Hospital | NULL | Pending | 18 | 75 | Both | Sitagliptin group:20;metformin group:20; | Phase 4 | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02882477 (ClinicalTrials.gov) | December 2016 | 17/7/2016 | Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy | Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy | Diabetes Mellitus;Iron Metabolism Disorders;Gastroduodenal Ulcer;Optic Atrophy;Sensorineural Hearing Loss;Platelet Dysfunction | Drug: Deferiprone;Drug: Acetylcysteine;Drug: Sitagliptin and Metformin | Hadassah Medical Organization | NULL | Not yet recruiting | 3 Years | N/A | Both | 20 | Phase 2;Phase 3 | Israel |